Osteonecrosis of the Jaw: Drug Risks, Triggers, and Stages

Osteonecrosis of the jaw is a condition in which jawbone tissue dies and fails to heal, leaving exposed or damaged bone that persists for weeks or longer. Nearly all cases today are linked to certain medications, particularly drugs prescribed to strengthen bones or fight cancer, and the condition was first recognized only in the early 2000s. Though rare, it can be painful and difficult to treat, and the risk rises sharply depending on which drug you take, why you take it, and what dental procedures you undergo while on it.

What the Condition Actually Looks Like

The formal name most clinicians use is medication-related osteonecrosis of the jaw, or MRONJ. The American Association of Oral and Maxillofacial Surgeons (AAOMS) defines it by three criteria: you have exposed bone (or bone that can be probed through a wound) in the jaw that has not healed within eight weeks, you have a current or past history of treatment with antiresorptive or antiangiogenic medications, and you have never received radiation therapy to the head or neck region. That last point matters because radiation can cause a visually similar problem called osteoradionecrosis, but the underlying cause and treatment differ.

Symptoms vary by stage. Early on, some people notice numbness, jaw heaviness, or loose teeth without any visible bone exposure. As the disease progresses, exposed bone appears in the mouth, often along the lower jaw, accompanied by pain, swelling, and sometimes infection with pus drainage. In advanced stages, the bone destruction can extend beyond the jaw, creating openings between the mouth and skin or sinuses, and in rare cases leading to fractures of the jawbone itself.

Which Medications Carry the Risk

Two broad categories of drugs are responsible for the vast majority of cases. The first is antiresorptive agents, drugs that slow bone breakdown. These include bisphosphonates (like zoledronic acid and alendronate) and denosumab. The second category is antiangiogenic drugs, medications that block the growth of new blood vessels, used mainly in cancer treatment.

Bisphosphonates and Denosumab

Bisphosphonates work by essentially shutting down osteoclasts, the cells responsible for breaking down and recycling old bone. This makes bones denser and is why these drugs are prescribed for osteoporosis and for cancer that has spread to bone. The trade-off is that the jaw, which undergoes more bone turnover than almost any other skeletal site, becomes vulnerable when that recycling process stalls.

Denosumab works differently at a molecular level but achieves a similar outcome: it also suppresses bone breakdown. Whether denosumab carries more or less risk than bisphosphonates depends on context. In cancer patients receiving high-dose treatment, a meta-analysis found that denosumab was associated with a higher incidence of jaw osteonecrosis than bisphosphonates, with the risk roughly 60 percent greater for denosumab users.

The picture reverses somewhat in osteoporosis patients, where doses are lower and exposure duration matters more. A large Taiwanese retrospective study found that in osteoporosis patients, denosumab users developed fewer cases of jaw osteonecrosis than bisphosphonate users in the long run, with a meaningful divergence appearing around the third year of treatment.

⁴

Across both drug types, the risk compounds with time. In cancer patients receiving denosumab, the incidence of jaw osteonecrosis ranged from about half a percent to 2 percent after one year of treatment and climbed to roughly 1 to 3 percent after three years. For zoledronic acid, a potent intravenous bisphosphonate, the three-year incidence in cancer patients reached about 1 to 2.3 percent.

⁵

Antiangiogenic and Targeted Cancer Drugs

A growing number of cases have been tied to drugs like bevacizumab and sunitinib, which fight tumors by choking off their blood supply. These drugs can impair the jaw’s ability to heal for a related but distinct reason: they suppress new blood vessel growth, and bone repair depends heavily on a healthy blood supply. Lab research on human jawbone cells shows that both bevacizumab and sunitinib dial down key proteins involved in bone formation, which could explain why healing stalls.

⁶

The risk appears to jump when antiangiogenic drugs are combined with bisphosphonates, which many cancer patients receive simultaneously. A systematic review of sunitinib-related cases found broad agreement that combining sunitinib with bisphosphonates significantly raises the odds of developing jaw osteonecrosis compared with either drug alone.

⁷

Cases tied solely to antiangiogenic drugs (without any bisphosphonate history) remain uncommon. A systematic review identified only 36 such patients across all published literature, and the mandible was the affected site in more than 80 percent of them. The evidence is still too thin to draw firm conclusions about best treatment, though surgical intervention appeared to outperform conservative management when recurrence was the concern.

⁸

Why the Jaw and Not Other Bones

This is one of the genuinely puzzling aspects of the condition. You take a drug that affects bone throughout your entire skeleton, yet the damage shows up almost exclusively in the jaw. The jawbone is unique in several ways. It undergoes far more bone remodeling than, say, a femur, partly because of the constant mechanical forces of chewing and partly because of the teeth. Teeth create a direct pathway between the bacteria-rich environment of the mouth and the underlying bone, a situation that exists nowhere else in the body. When a tooth is extracted or an infection develops, the jawbone needs to mount a robust healing response, and that response depends on exactly the processes these medications suppress: bone recycling, blood vessel formation, and immune activity at the site.

The Biggest Trigger You Can Control

Dental extractions are, by a wide margin, the most common event that precedes jaw osteonecrosis. A retrospective study of 240 patients found dramatically different risks depending on why they were taking antiresorptive drugs. Among osteoporosis patients who underwent tooth extraction, roughly 2.7 percent developed MRONJ per person-year. Among cancer patients with bone metastases who had extractions, the rate was about 26 percent per person-year, nearly ten times higher.

⁹

Other invasive dental procedures like implant placement and periodontal surgery also carry risk, though extractions dominate the data. Even poorly fitting dentures that create pressure sores on the gums can trigger the process by breaching the soft tissue and exposing bone to oral bacteria. This is why dental screening before starting these medications, and careful dental hygiene while taking them, is so heavily emphasized in clinical guidelines.

¹⁰

Other Risk Factors

Diabetes stands out as a significant amplifier. The disease damages small blood vessels, impairs immune function, and disrupts bone cell activity through overlapping pathways. All of these effects compound the jaw’s already compromised healing capacity in someone on antiresorptive drugs.

¹¹

Conditions that impair blood vessel health more generally may also raise risk. A study that looked at diseases affecting blood vessel growth found that patients with such conditions had roughly 2.5 times the odds of developing jaw osteonecrosis, even when bisphosphonate use was taken out of the equation. Rheumatoid arthritis and high cholesterol showed especially elevated odds in that analysis.

¹²

Smoking and use of corticosteroids are also frequently cited, as both impair wound healing. Older age and female sex appear more often in case series, though some of that demographic skew likely reflects the fact that osteoporosis treatment disproportionately involves older women.

Detecting It Early

One of the trickier aspects of jaw osteonecrosis is that it can begin before any bone is visibly exposed in the mouth. This early phase, sometimes called stage 0, involves symptoms like jaw pain, tooth loosening, or sinus tract formation without the telltale exposed bone. Catching it at this point can improve outcomes, but it requires imaging rather than just a visual exam.

Cone-beam CT and MRI are the most sensitive tools for early detection. A systematic review of imaging studies found that osteosclerosis, a pattern of abnormally dense bone, was the most commonly observed sign in early-stage disease, showing up in 75 percent of studies using cone-beam CT and nearly 90 percent of studies using conventional CT. MRI adds a different dimension, detecting changes in bone marrow signal that may precede structural damage visible on CT.

¹³

No single imaging technique has proven specific enough to confirm stage 0 on its own. A review of the evidence concluded that while osteosclerosis was the most frequently observed sign across all imaging modalities, no technique offered features unique enough to definitively diagnose the earliest stage of the disease.

¹⁴

Treatment Depends Heavily on Stage

For early, mild disease where the bone exposure is small and there is no infection, conservative management tends to work reasonably well. This usually means antibacterial mouth rinses, antibiotics if infection is present, and careful monitoring. For more advanced disease with significant bone destruction, pain, or infection, surgery becomes the preferred approach. Procedures range from removing loose, dead fragments of bone (sequestrectomy) to resecting larger portions of the jaw in severe cases.

A systematic review comparing the two approaches found that about 62 percent of surgically treated patients achieved healing, compared with roughly 29 percent of conservatively managed patients. That gap sounds stark, but it should be read with caution: sicker patients with worse disease tend to end up in surgery, muddying the comparison.

¹⁵

A separate systematic review reached a more nuanced framing: conservative treatment appears adequate for early-stage disease in patients without symptoms, while surgical therapy seems superior for managing more advanced stages.

¹⁶

For intravenous bisphosphonate cases specifically, surgical debridement and bone removal have reported success rates ranging from 58 to 100 percent in published series, though those numbers span very different definitions of “success” and follow-up periods.

¹⁷

Do Drug Holidays Help?

This is one of the most debated questions in the field. The idea is intuitive: if you stop the offending medication for a few months before a tooth extraction, maybe the jaw will recover enough healing capacity to survive the procedure. In practice, the evidence is discouraging. A meta-analysis pooling data from observational studies found no statistically significant difference in the development of jaw osteonecrosis between patients who took a drug holiday and those who did not. The authors concluded that drug holidays from antiresorptive medications cannot be recommended as a way to reduce risk.

¹⁸

Animal research tells a similar story. A study using an osteoporotic rat model found that a bisphosphonate holiday partially restored osteoclast activity (the bone-recycling cells start working again to some degree), but this recovery did not prevent the development of osteonecrosis-like lesions after tooth extraction.

¹⁹

The reason drug holidays fall short probably relates to how long bisphosphonates linger. These drugs bind tightly to bone mineral and can remain in bone tissue for years after the last dose. Stopping the drug for three or six months does not meaningfully clear it from the jaw. Denosumab, by contrast, leaves the body faster once discontinued, but stopping it carries its own risk of rapid bone loss and rebound fractures in the spine.

How It Differs from Osteoradionecrosis

Radiation therapy to the head and neck can cause a strikingly similar-looking condition called osteoradionecrosis. Both involve exposed, non-healing jawbone, and distinguishing them can be difficult at a glance. But a study comparing the two found meaningful clinical differences. Jaw osteonecrosis from medications was more often preceded by a tooth extraction, affected more women (reflecting the demographics of osteoporosis treatment), and was more frequently associated with pain. Osteoradionecrosis was more likely to require surgical resection, while medication-related cases were more often managed with minimal debridement. On CT imaging, periosteal reaction — new bone forming along the outer surface of the jaw — was seen only in medication-related cases.

²⁰

The Quality-of-Life Toll

Jaw osteonecrosis can be far more burdensome than its rarity might suggest. A study assessing quality of life in cancer patients with the condition found that psychological distress was the most severely affected dimension, with an alarmingly significant impact.

²¹

A larger assessment using standardized quality-of-life instruments painted a more detailed picture. Patients with jaw osteonecrosis reported significantly worse scores across multiple domains, with pain, eating discomfort, self-consciousness about their mouth, unsatisfactory diet, interrupted meals, irritability, and decreased life satisfaction all standing out. Overall quality of life dropped progressively with disease stage. Patients with stage 3 disease reported quality-of-life scores roughly half those of patients without the condition. Pain and anxiety were the two dimensions that drove the decline most.

²²

Genetic Susceptibility

Not everyone on these drugs develops jaw osteonecrosis, and genetics likely explains part of the variability. Researchers have identified several genetic variations that may increase susceptibility. In one study of multiple myeloma patients on bisphosphonate therapy, variations in five genes were examined together. Patients carrying higher-risk combinations across these genes had jaw osteonecrosis rates of 57 percent, compared with just 10 percent in those with lower-risk profiles, an adjusted odds ratio of about 11.

²³

One gene that has received particular attention is MMP2, which encodes a protein involved in both bone remodeling and blood vessel maintenance. The hypothesis is appealing because bisphosphonates are also linked to heart rhythm abnormalities, and MMP2 is the only gene known to be connected to both bone disease and atrial fibrillation, suggesting it could be a shared vulnerability point.

²⁴

That said, the search for reliable blood-based biomarkers to predict who will develop the condition has been frustrating. A systematic review examining seven proposed biomarkers across bone turnover, blood vessel growth, and hormonal categories found conflicting results for most of them. No single blood test can currently tell a clinician which patients are at high risk.

²⁵

The Informed Consent Gap

One underappreciated dimension of this condition is how often patients are not adequately warned about it. A systematic review examining dentist awareness of jaw osteonecrosis found concerning levels of ignorance among the very professionals who perform the dental procedures most likely to trigger it. The review highlighted, from an ethical standpoint, that informed consent for dental procedures in patients on these medications is not a simple checkbox. It is an ongoing communication process that should cover the risks, the alternatives, and the consequences of acting or not acting.

²⁶

This creates a practical takeaway worth remembering: if you are on bisphosphonates, denosumab, or antiangiogenic cancer drugs, tell every dentist and oral surgeon you see, and ask specifically what precautions they recommend before any procedure that involves the jawbone. Many patients do not realize that a drug prescribed by their oncologist or rheumatologist could affect what happens in a dentist’s chair.

Children and Low-Dose Patients

Jaw osteonecrosis has been almost exclusively reported in adults, but bisphosphonates are also prescribed to children with conditions like osteogenesis imperfecta (brittle bone disease). A systematic review looking at pediatric cases found that the risk profile cannot be directly compared to adults because the pediatric skeleton has fundamentally different bone turnover rates and dynamics, making dose comparisons difficult to interpret.

²⁷

In adults taking low-dose oral bisphosphonates for garden-variety osteoporosis, the risk remains very low in absolute terms. The overwhelming majority of severe cases occur in cancer patients receiving high-dose intravenous formulations on aggressive schedules. If your doctor has prescribed a weekly or monthly pill for bone density, the risk of jaw osteonecrosis is real but extremely small, and in most cases the skeletal protection the drug provides far outweighs it. The balance tips differently for cancer patients on monthly intravenous infusions, where the cumulative exposure is many times greater and the risk becomes more clinically meaningful.